384 related articles for article (PubMed ID: 28851502)
1. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents.
Beretta GL; Cassinelli G; Pennati M; Zuco V; Gatti L
Eur J Med Chem; 2017 Dec; 142():271-289. PubMed ID: 28851502
[TBL] [Abstract][Full Text] [Related]
2. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance?
Brózik A; Hegedüs C; Erdei Z; Hegedus T; Özvegy-Laczka C; Szakács G; Sarkadi B
Expert Opin Drug Metab Toxicol; 2011 May; 7(5):623-42. PubMed ID: 21410427
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
6. Interaction of tyrosine kinase inhibitors with the MDR- related ABC transporter proteins.
Wang XK; Fu LW
Curr Drug Metab; 2010 Sep; 11(7):618-28. PubMed ID: 20812904
[TBL] [Abstract][Full Text] [Related]
7. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
Deng J; Shao J; Markowitz JS; An G
Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
9. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
10. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells.
Wu S; Fu L
Mol Cancer; 2018 Feb; 17(1):25. PubMed ID: 29455646
[TBL] [Abstract][Full Text] [Related]
12. Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration.
Krchniakova M; Skoda J; Neradil J; Chlapek P; Veselska R
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365759
[TBL] [Abstract][Full Text] [Related]
13. Reversing multidrug resistance by tyrosine kinase inhibitors.
He M; Wei MJ
Chin J Cancer; 2012 Mar; 31(3):126-33. PubMed ID: 22237041
[TBL] [Abstract][Full Text] [Related]
14. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
Cihalova D; Staud F; Ceckova M
Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678
[TBL] [Abstract][Full Text] [Related]
15. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
Fleisher B; Unum J; Shao J; An G
J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.
Ozvegy-Laczka C; Cserepes J; Elkind NB; Sarkadi B
Drug Resist Updat; 2005; 8(1-2):15-26. PubMed ID: 15939339
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
Azzariti A; Porcelli L; Simone GM; Quatrale AE; Colabufo NA; Berardi F; Perrone R; Zucchetti M; D'Incalci M; Xu JM; Paradiso A
Cancer Chemother Pharmacol; 2010 Jan; 65(2):335-46. PubMed ID: 19495754
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia.
Polillo M; Galimberti S; Baratè C; Petrini M; Danesi R; Di Paolo A
Int J Mol Sci; 2015 Sep; 16(9):22811-29. PubMed ID: 26402671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
